Skip to main content

Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., April 06, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs. DeLorenzo will oversee external relations, corporate communications, advocacy, and corporate social responsibility. She will be responsible for developing and leading the company’s global public affairs strategy and providing strategic communications counsel to the executive management team.
Robert G. Kramer Sr., president and chief executive officer at Emergent BioSolutions, stated, “On behalf of the management team, I am pleased to welcome Nina to Emergent. Her deep bench of public affairs and public policy experience uniquely qualify her for this critical role, and we look forward to both her leadership and strategic counsel during a pivotal time for our company. As we continue in pursuit of our vision to protect or enhance 1 billion lives by 2030, I am confident that her wide range of expertise will strengthen our position as a trusted leader in the public health space.”“I am thrilled to join the Emergent team, especially at this critical time, where our mission—to protect and enhance life—is front and center in the fight against COVID-19,” said DeLorenzo. “Emergent’s longstanding track record of success, enabling the U.S. government and others to address our nation’s public health threats provides a real and very relevant opportunity to strengthen its public footprint, and I am proud to join this important effort.”DeLorenzo has 25 years of experience in public affairs, government affairs, and communications in the public and private sectors. She most recently served as chief of staff, external affairs at Sanofi in Paris, France. Her prior experience includes government affairs, communications, and public policy roles at AbbVie, Pfizer Inc, Schering-Plough Corp. (now Merck), and at the Pharmaceutical Research and Manufacturers of America (PhRMA). DeLorenzo served in the administration of President George W. Bush at the White House Coalition Information Center and at the U.S. Department of State. Prior to this, she held roles in government and on political campaigns.About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.comMedia Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.